These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23983262)

  • 1. Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo.
    Oueslati A; Schneider BL; Aebischer P; Lashuel HA
    Proc Natl Acad Sci U S A; 2013 Oct; 110(41):E3945-54. PubMed ID: 23983262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated α-Synuclein-selective Autophagic Degradation.
    Dahmene M; Bérard M; Oueslati A
    J Biol Chem; 2017 Mar; 292(9):3919-3928. PubMed ID: 28154193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
    Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP
    Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
    Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
    PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 2 modulates α-synuclein protein levels by regulating its mRNA production.
    Kofoed RH; Zheng J; Ferreira N; Lykke-Andersen S; Salvi M; Betzer C; Reimer L; Jensen TH; Fog K; Jensen PH
    Neurobiol Dis; 2017 Oct; 106():49-62. PubMed ID: 28648742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system.
    Inglis KJ; Chereau D; Brigham EF; Chiou SS; Schöbel S; Frigon NL; Yu M; Caccavello RJ; Nelson S; Motter R; Wright S; Chian D; Santiago P; Soriano F; Ramos C; Powell K; Goldstein JM; Babcock M; Yednock T; Bard F; Basi GS; Sham H; Chilcote TJ; McConlogue L; Griswold-Prenner I; Anderson JP
    J Biol Chem; 2009 Jan; 284(5):2598-2602. PubMed ID: 19004816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron-induced oxidative stress contributes to α-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2.
    Wang R; Wang Y; Qu L; Chen B; Jiang H; Song N; Xie J
    Neurochem Int; 2019 May; 125():127-135. PubMed ID: 30797969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
    Hong CT; Chen KY; Wang W; Chiu JY; Wu D; Chao TY; Hu CJ; Chau KD; Bamodu OA
    Cells; 2020 Mar; 9(3):. PubMed ID: 32192190
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic deletion of Polo-like kinase 2 reduces alpha-synuclein serine-129 phosphorylation in presynaptic terminals but not Lewy bodies.
    Weston LJ; Stackhouse TL; Spinelli KJ; Boutros SW; Rose EP; Osterberg VR; Luk KC; Raber J; Weissman TA; Unni VK
    J Biol Chem; 2021; 296():100273. PubMed ID: 33428941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icariin Inhibits Overexpression and Aggregation of α-Synuclein in A53T α-Synuclein Transgenic Mice by Regulating Parkin and PLK2.
    Ma D; Shen C; Zhang X; Zhang L; Li L
    J Integr Neurosci; 2023 Nov; 22(6):166. PubMed ID: 38176950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein.
    Rodríguez-Nogales C; Garbayo E; Martínez-Valbuena I; Sebastián V; Luquin MR; Blanco-Prieto MJ
    Int J Pharm; 2016 Nov; 514(1):142-149. PubMed ID: 27863657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing synuclein at the synapse with PLK2.
    Looyenga BD; Brundin P
    Proc Natl Acad Sci U S A; 2013 Oct; 110(41):16293-4. PubMed ID: 24072649
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.
    Landeck N; Hall H; Ardah MT; Majbour NK; El-Agnaf OM; Halliday G; Kirik D
    Mol Neurodegener; 2016 Aug; 11(1):61. PubMed ID: 27549140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei.
    Fitzgerald K; Bergeron M; Willits C; Bowers S; Aubele DL; Goldbach E; Tonn G; Ness D; Olaharski A
    Toxicol Appl Pharmacol; 2013 May; 269(1):1-7. PubMed ID: 23466428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-101-3p Contributes to
    Zhang M; Liu W; Zhang Q; Hu H
    J Healthc Eng; 2021; 2021():6147434. PubMed ID: 34234930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2.
    Wang S; Xu B; Liou LC; Ren Q; Huang S; Luo Y; Zhang Z; Witt SN
    Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16119-24. PubMed ID: 22988096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.
    Buck K; Landeck N; Ulusoy A; Majbour NK; El-Agnaf OM; Kirik D
    Neurobiol Dis; 2015 Jun; 78():100-14. PubMed ID: 25818009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen synthase kinase 3 β activity is essential for Polo-like kinase 2- and Leucine-rich repeat kinase 2-mediated regulation of α-synuclein.
    Kofoed RH; Betzer C; Ferreira N; Jensen PH
    Neurobiol Dis; 2020 Mar; 136():104720. PubMed ID: 31881263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DYRK1A-mediated PLK2 phosphorylation regulates the proliferation and invasion of glioblastoma cells.
    Tan S; Zhao J; Wang P
    Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37387444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.